Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

Archives of Ophthalmology

Volumn 130, Issue 5, 2012, Pages 592-598

  Okada, Annabelle A ^a   Goto, Hiroshi ^b   Ohno, Shigeaki ^d   Mochizuki, Manabu ^c  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD CELL COUNT; BRADYCARDIA; BREATHING DISORDER; COLITIS; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; TONSILLITIS; URTICARIA; UVEITIS; UVEORETINITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RETINITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84860905766     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.2698     Document Type: Article

References (40)

1. Ministry of Health, Labour, and Welfare, Japan. Report of the Administration for Insurance and Health. 2008 http://www.mhlw.go.jp/toukei/ saikin/hw/eisei/08/dl/data-007.pdf. Accessed August 27, 2010.
2. Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51(1):41-44. (Pubitemid 46281230)
3. Behçet's Disease Research Committee of Japan. Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol. 1974;18:291-294.
4. Okada AA. Behçet's disease: general concepts and recent advances. Curr Opin Ophthalmol. 2006;17(6):551-556. (Pubitemid 44655589)
5. Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):709-714.
6. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903-912. (Pubitemid 41057986)
7. Sobrin L, Kim EC, ChristenW, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125(7):895-900. (Pubitemid 47076425)
8. Okada AA. The dream of biologics in uveitis. Arch Ophthalmol. 2010;128(5):632-635.
9. Nakamura S, Sugita M, Tanaka T, Ohno S. Enhanced production of in vitro tumor necrosis factor-α from monocytes in Behçet's disease [in Japanese]. Nihon Ganka Gakkai Zasshi. 1992;96(10):1282-1285.
10. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362-1368. (Pubitemid 38879203)
11. JCN Network. Tanabe Seiyaku announces anti TNF-α monoclonal antibody preparation REMICADE(R) for drip infusion 100 receives approval as additional indication of treating Behçet's disease with refractory uveoretinitis. http://japancorp.net/article.asp?Art-ID=14059. Accessed September 7, 2010.
12. Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Behçet's disease after one year of administration. Jpn J Ophthalmol. 2010;54(5):502-504.
13. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94(3):284-288.
14. Tanaka H, Sugita S, Yamada Y, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease. Nihon Ganka Gakkai Zasshi. 2010;114(2):87-95.
15. Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95(2):205-208.
16. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease. Br J Ophthalmol. 2011;95(4):549-552.
17. Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol. 2011;95(9):1245-1250.
18. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140(5):404-406. (Pubitemid 38268925)
19. Wechsler B, Sablé-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22(4)(suppl 34):S14-S16.
20. Tugal-Tutkun I, Mudun A, UrganciogluM, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478-2484. (Pubitemid 41117435)
21. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26(3):83-92.
22. Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin AP, Guillevi L. Infliximab in the treatment of posterior uveitis in Behçet's disease: long term follow up in four patients. Presse Med. 2005;34(13):916-918. (Pubitemid 41059812)
23. Merino G, Varas G, Díaz G, et al. Effectiveness of infliximab in patients with Behçet syndrome and severe uveoretinitis: report of five cases. Rev Med Chil. 2006;134(7):875-882. (Pubitemid 44357844)
24. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161-1164. (Pubitemid 47050622)
25. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51(3):191-196. (Pubitemid 46889493)
26. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146(6):845-850.e1.
27. Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int. 2008;29(1):53-57.
28. Morimura Y, Okada AA, Kawahara S, et al. Tuberculin skin testing in uveitis patients and treatment of presumed intraocular tuberculosis in Japan. Ophthalmology. 2002;109(5):851-857. (Pubitemid 34465215)
29. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-α therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10(5):657-660. (Pubitemid 39276478)
30. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305-312.
31. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum. 2002;46(10):2565-2570. (Pubitemid 36118917)
32. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38(5):502-508.
33. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56(9):1226-1231. (Pubitemid 47300423)
34. Hijikata K, Masuda K. Visual prognosis in Behçet's disease: effects of cyclophosphamide and colchicines. Jpn J Ophthalmol. 1978;22:506-519. (Pubitemid 9051265)
35. Fujino Y, Joko S, Masuda K, et al. Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease. Jpn J Ophthalmol. 1999;43(4):318-326. (Pubitemid 29329393)
36. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-α therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109(12):2342-2346. (Pubitemid 35417121)
37. Li Z, Liu B, Maminishkis A, et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol. 2008;181(7):5147-5157.
38. Keino H, Watanabe T, Taki W, Okada AA. Effect of infliximab on gene expression profiling in Behçet's disease. Invest Ophthalmol Vis Sci. 2011;52(10):7681-7686.
39. Sekiguchi N, Kawauchi S, Furuya T, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-α monoclonal antibody, infliximab. Rheumatology (Oxford). 2008;47(6):780-788. (Pubitemid 351796361)
40. Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009;4(11):e7984 http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2776509/?tool=pubmed. Accessed February 16, 2012.